Ferroptosis in cancer cells triggers PGE2 production for tumour immune escape

Ferroptosis, a form of cell death induced by overwhelming membrane lipid peroxidation, is a vulnerability of many cancers, including cancers resistant to current molecular and immune-based therapies 1–7 . Triggering of ferroptosis therefore provides an opportunity to achieve elimination of difficult-to-treat cancers 1–4,8,9 . Studies in mouse cancer models have demonstrated that anticancer immunity, mediated by dendritic cells (DCs) and CD8 + T cells, is essential for effective tumour eradication by ferroptosis-inducing strategies 10–13 . However, ferroptotic cells limit this response 8–10,14 , resulting in immune escape and tumour growth through mechanisms that remain unclear. Here we demonstrate that ferroptotic cancer cells activate a molecular program resulting in aberrant production of prostaglandin E 2 (PGE 2 ), which limits the stimulation of anticancer CD8 + T cell responses by type 1 conventional DCs (cDC1s), thereby promoting immune escape. In ferroptotic cancer cells, lipid peroxidation-mediated membrane permeabilization enables Ca 2+ influx, which activates p38 MAPK signalling and thereby drives PGE 2 production. This signalling axis is uncoupled from cancer cell death and can be targeted to selectively interfere with immune-inhibitory PGE 2 production while preserving ferroptotic cancer cell elimination. In the context of cancer cell ferroptosis, ablation of PGE 2 production or disrupting PGE 2 signalling restores cDC1-mediated anticancer CD8 + T cell responses and leads to effective tumour elimination. Our findings identify a key mechanism that limits antitumour immunity and prevents tumour elimination upon ferroptosis induction in cancer cells, which could be exploited for cancer therapy.

Authors

Institutions

Publication Details

Journal
Nature
Published
2026-11-18
DOI
https://doi.org/10.1038/s41586-026-11333-6
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ferroptosis in cancer cells triggers PGE2 production for tumour immune escape

Anna Hirschberger, Lukas Ramsauer, Silvia von Karstedt, Marcus Conrad et al.
Nature
Ferroptosis and cancer prognosis
article

Ferroptosis in cancer cells triggers PGE2 production for tumour immune escape

Anna Hirschberger, Lukas Ramsauer, Silvia von Karstedt, Marcus Conrad, Jan P. Böttcher, Gabriela Maria Wiedemann, Scott J. Dixon, Julia Esser‐von Bieren, Christina M. Bebber, Nicolas Snaidero, Kevin Schmid, Toshitaka Nakamura, Gregor Ebert, Percy Alexander Knolle, Anna‐Marie Pedde, Sainitin Donakonda, Martina Anton, Felix Bayerl, Benedikt Spitzlberger, Sebastian B. Lacher, Nadine Nuschele, María Parra Reyes, Daina Chakma
article en

Abstract

Ferroptosis, a form of cell death induced by overwhelming membrane lipid peroxidation, is a vulnerability of many cancers, including cancers resistant to current molecular and immune-based therapies 1–7 . Triggering of ferroptosis therefore provides an opportunity to achieve elimination of difficult-to-treat cancers 1–4,8,9 . Studies in mouse cancer models have demonstrated that anticancer immunity, mediated by dendritic cells (DCs) and CD8 + T cells, is essential for effective tumour eradication by ferroptosis-inducing strategies 10–13 . However, ferroptotic cells limit this response 8–10,14 , resulting in immune escape and tumour growth through mechanisms that remain unclear. Here we demonstrate that ferroptotic cancer cells activate a molecular program resulting in aberrant production of prostaglandin E 2 (PGE 2 ), which limits the stimulation of anticancer CD8 + T cell responses by type 1 conventional DCs (cDC1s), thereby promoting immune escape. In ferroptotic cancer cells, lipid peroxidation-mediated membrane permeabilization enables Ca 2+ influx, which activates p38 MAPK signalling and thereby drives PGE 2 production. This signalling axis is uncoupled from cancer cell death and can be targeted to selectively interfere with immune-inhibitory PGE 2 production while preserving ferroptotic cancer cell elimination. In the context of cancer cell ferroptosis, ablation of PGE 2 production or disrupting PGE 2 signalling restores cDC1-mediated anticancer CD8 + T cell responses and leads to effective tumour elimination. Our findings identify a key mechanism that limits antitumour immunity and prevents tumour elimination upon ferroptosis induction in cancer cells, which could be exploited for cancer therapy.

Nature
University of Cologne (DE), Tohoku University (JP), TUM Klinikum (DE), Helmholtz Zentrum München (DE), Universitätsklinikum Tübingen (DE), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE), Hertie Institute for Clinical Brain Research (DE), University Hospital Cologne (DE), Technical University of Munich (DE), University of Tübingen (DE), Stanford University (US), University of Lausanne (CH)
European Commission, Deutsche Forschungsgemeinschaft, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Eberhard Karls Universität Tübingen, HORIZON EUROPE Framework Programme
Good health and well-being
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon